Blue Chip Stock Hansoh Pharma HKG:3692 0 Updated: January 28, 2023 Ex Dividend: N/A Quick glance, Price-to-earnings (P/E ratio): 33.88 Price-to-Book ratio : 4.33 preferably <1 although some value investors like it till <3 Earnings per Share (EPS): 0.51 BETA: 0.60 A Beta greater than 1.0 might indicate that the stock is more volatile than […]
Blue Chip Stock Sino Biopharm HKG:1177 Updated: January 28, 2023 Ex Dividend: N/A Quick glance, Price-to-earnings (P/E ratio): 11.42 Price-to-Book ratio : 2.73 preferably <1 although some value investors like it till <3 Earnings per Share (EPS): 0.43 BETA: 0.63 A Beta greater than 1.0 might indicate that the stock is more volatile than the […]
Blue Chip Stock CSPC Pharma HKG:1093 August 2020 the first Interim Dividend was announced. For CSPC Pharma Dividend Growth and Safety look promising, but is this a dividend stock that will keep growing? It did for the last 5 years. Well with a P/E and Price-to-book ratios like this, the price seems higher than the […]
HKG:3613 Tong Ren Tang 1H 2022 a special dividend was announced. That while net profit growth and EPS were decreasing with 19%. D/E is at a lovely 0.09 and P/B 2.3.
HKG:1681 Consun Pharm The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Company’s subsidiaries include Brilliant Reach Group Limited, Century International Develop Limited and Grand Reach Company Limited. Through its subsidiaries, the Company is also engaged in the research and development of pharmaceutical products.No interim dividend for the six months ended
30 June 2022. There might be the distribution of a final dividend based on the dividend
level in previous years at the Board meeting to be held for reviewing the results for the
year ending 31 December 2022.
HKG:1177 Sino Biopharm The Group’s business works in a fully integrated chain which spans from R&D to manufacture and sales of pharmaceutical products, covering a vast array of biopharmaceutical, chemical and modernized Chinese medicines. Interim result 2022 are favorable for dividends (+200%) yet EPS fell 77%
HKG:1099 SINOPHARM Dividend is in RMB also here. Other than that, things look nice. Not too splendid on the yield side , but consistent growth in dividend. So sit and wait till the time is right.
HKG:0867 CMS Results 1H 2022 are okay. Dividends got up 6% (interim), EPS and Net Profit are up 7%. Debt/Equity remained stable. This looks promising toward the years ending in terms of higher proceeds of holding this stock. (Average 5-yr Dividend Growth is almost 20%)